Maraviroc Tarbis

Maraviroc, the active ingredient in Maraviroc Tarbis, is a CCR5 antagonist presented as an oral formulation for oral use. It treats HIV‑1 infection in combination with other antiretroviral agents. Maraviroc works by blocking the CCR5 co‑receptor, preventing viral entry into CD4+ cells and reducing viral replication.

GNH USA supplies Maraviroc Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maraviroc is a CCR5 antagonist used in the management of HIV‑1 infection.

- HIV‑1 infection (treatment‑naïve): reduces viral load when combined with standard antiretroviral regimens. - HIV‑1 infection (treatment‑experienced): provides an alternative mechanism for patients with resistance to other agents. - HIV‑1 infection (CCR5‑tropic virus): effective when the virus utilizes the CCR5 co‑receptor for cell entry.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: may occur with or without vomiting. - Diarrhea: usually transient. - Fatigue: general tiredness. - Cough: dry or productive. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe allergic reaction: anaphylaxis, angioedema. - Depression or suicidal thoughts: monitor mental health. - QT interval prolongation: risk of cardiac arrhythmia. - Stevens‑Johnson syndrome: severe skin reaction. - Severe respiratory distress: rare pulmonary complications.

Before initiating therapy, clinicians should assess patient suitability and monitor for adverse events.

- Liver function: evaluate baseline enzymes and monitor periodically. - Cardiac health: obtain ECG to assess QT interval, especially with other QT‑prolonging drugs. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy considerations: use only if potential benefit justifies potential risk. - Drug interactions: review concomitant medications for CYP3A4 modulators. - Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Maraviroc may interact with several co‑administered medicines; careful review is required.

Major Interactions (Avoid): - Protease inhibitors (ritonavir, cobicistat): markedly increase maraviroc plasma levels. - Strong CYP3A inducers (rifampin, carbamazepine, phenytoin): substantially reduce exposure. - QT‑prolonging agents (quinidine, amiodarone): increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Other antiretrovirals (efavirenz, nevirapine): may alter maraviroc concentrations. - Hepatitis C protease inhibitors (telaprevir, boceprevir): require dose adjustment. - Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.